MRI-Guided radiation aims to cut bowel side effects in prostate cancer

NCT ID NCT06171269

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using MRI scans to guide radiation can lower the dose to healthy parts of the prostate while targeting cancer spots. The goal is to reduce bowel-related side effects without losing cancer control. About 60 men with intermediate- or high-risk prostate cancer will receive daily radiation for 4 weeks, plus hormone therapy for 6–24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy
What this could lead to: If successful, this approach could reduce bowel side effects from radiation while still controlling prostate cancer, improving quality of life.
What could go wrong: This is a small, early-phase study with only 60 participants, so results may not apply to everyone. The lower radiation dose might also be less effective at controlling cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

University of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.